192 related articles for article (PubMed ID: 28766886)
1. Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.
Teicher BA; Silvers T; Selby M; Delosh R; Laudeman J; Ogle C; Reinhart R; Parchment R; Krushkal J; Sonkin D; Rubinstein L; Morris J; Evans D
Cancer Med; 2017 Aug; 6(8):1952-1964. PubMed ID: 28766886
[TBL] [Abstract][Full Text] [Related]
2. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
[TBL] [Abstract][Full Text] [Related]
4. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.
Krushkal J; Silvers T; Reinhold WC; Sonkin D; Vural S; Connelly J; Varma S; Meltzer PS; Kunkel M; Rapisarda A; Evans D; Pommier Y; Teicher BA
Clin Epigenetics; 2020 Jun; 12(1):93. PubMed ID: 32586373
[TBL] [Abstract][Full Text] [Related]
5. Bromodomain and hedgehog pathway targets in small cell lung cancer.
Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
[TBL] [Abstract][Full Text] [Related]
6. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
7. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
Qiu Z; Lin A; Li K; Lin W; Wang Q; Wei T; Zhu W; Luo P; Zhang J
Drug Des Devel Ther; 2019; 13():2021-2041. PubMed ID: 31417239
[TBL] [Abstract][Full Text] [Related]
8. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
Polley E; Kunkel M; Evans D; Silvers T; Delosh R; Laudeman J; Ogle C; Reinhart R; Selby M; Connelly J; Harris E; Fer N; Sonkin D; Kaur G; Monks A; Malik S; Morris J; Teicher BA
J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27247353
[TBL] [Abstract][Full Text] [Related]
9. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA expression and clinical outcome of small cell lung cancer.
Lee JH; Voortman J; Dingemans AM; Voeller DM; Pham T; Wang Y; Giaccone G
PLoS One; 2011; 6(6):e21300. PubMed ID: 21731696
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer.
Kim KH; Kim JO; Park JY; Seo MD; Park SG
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216379
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
16. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH; Parham C; Shocron E; McMahon G; Patel N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
[TBL] [Abstract][Full Text] [Related]
17. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.
Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Sato I; Tani N; Ogura Y; Hirose K; Takeda T
Thorac Cancer; 2020 Sep; 11(9):2740-2742. PubMed ID: 32706170
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R
J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506
[TBL] [Abstract][Full Text] [Related]
20. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
